Nivolumab FDA Approval Status (2026) – Approved or Not?
FDA Regulatory Database

Is Nivolumab
FDA approved?

DrugStatusIndex.com provides a plain-English status page for Nivolumab, including FDA approval status, prescription classification, compounding context, pricing information, and regulatory notes.

Needs FDA status review
FDA status
Oncology / hematology medication
Drug category
2026-05-26
Last reviewed
Drug status summary

Nivolumab

Needs FDA status review

Nivolumab is included as a DrugStatusIndex entry for FDA-status review, page creation, and consumer-facing status clarification.

Brand names
Nivolumab
Prescription status
Available by prescription depending on provider evaluation, indication, and current FDA-approved product status.
Compounded status
Verify exact FDA approval, listing status, route, and indication before publishing
Confusion level
Medium
FDA Approved Approved for commercial use in the US
Not Approved Not cleared by FDA for use
Investigational Under review or in clinical trials
Rx Only Prescription required — not OTC
FDA approval status

Nivolumab approval status and regulatory context

This page is structured for LPagery Pro and uses your CSV fields to create a consistent, scalable drug-status page that matches the current DrugStatusIndex.com home page design.

What DrugStatusIndex currently shows

Nivolumab is included as a DrugStatusIndex entry for FDA-status review, page creation, and consumer-facing status clarification.

Regulatory note: Users should verify labeling, approved indications, and current FDA guidance directly through official FDA resources.
FDA status
Needs FDA status review
Drug category
Oncology / hematology medication
Prescription status
Available by prescription depending on provider evaluation, indication, and current FDA-approved product status.
Availability note
Availability depends on prescription eligibility, pharmacy supply, insurance coverage, and current market access.

Index review fields

Review status
Needs review
Last checked
2026-04-28
Published
No
Page URL
https://drugstatusindex.com/is-nivolumab-fda-approved/
Pricing and access

Nivolumab pricing information

Pricing can vary by dose, pharmacy, insurance coverage, manufacturer savings, coupon programs, market availability, and current supply conditions.

Retail estimate
$6,000-$15,000 per infusion/claim

Estimated cash or retail pricing range when available.

Coupon estimate
Coupon pricing usually not applicable; oncology billing channel

Discount-card or pharmacy coupon estimate when available.

Pricing last checked
May 2026

Pricing data should be rechecked before making financial or treatment decisions.

Pricing summary

Nivolumab estimated cash pricing: $6,000-$15,000 per infusion/claim. Discount/coupon estimate: Coupon pricing usually not applicable; oncology billing channel. Pricing varies by dose, quantity, pharmacy, location, insurance, and current savings programs.

Coverage and savings notes

Manufacturer savings: BMS patient support may apply

Insurance note: Medical benefit billing; authorization and site-of-care rules apply

Sources and verification

Verify Nivolumab directly with trusted source material

DrugStatusIndex.com is an informational resource. FDA status, availability, and pricing should be independently verified using official FDA resources, pharmacy data, prescribing information, and licensed healthcare guidance.

FDA / regulatory source
https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
Pricing source
https://www.drugs.com/price-guide/opdivo | https://www.opdivo.com/support-and-resources

Preview this drug-status page

Use this button to preview the generated LPagery page for Nivolumab and confirm the page output before wider publishing.

Preview Page →
Informational resource only
DrugStatusIndex.com reflects publicly available FDA regulatory data and does not provide medical advice, diagnosis, treatment recommendations, pharmacy recommendations, or legal/regulatory advice. Always consult a licensed healthcare provider before making any medical decision.
Scroll to Top